Connect
MJA
MJA

Metformin use as an adjunct to insulin treatment in selected patients with type 1 diabetes mellitus

Jenny E Gunton and Stephen M Twigg
Med J Aust 2003; 178 (11): 591-592.
Published online: 2 June 2003

To the Editor: Metformin is a commonly prescribed oral hypoglycaemic agent used to treat type 2 diabetes mellitus. Its major effect is on hepatic glucose production and thereby fasting blood glucose level (f-BGL). Metformin does not commonly cause weight gain, and may be associated with significant weight loss.1

  • Jenny E Gunton
  • Stephen M Twigg


Correspondence: 

Acknowledgements: 

Jenny E Gunton is supported by the National Health and Medical Research Council CJ Martin Fellowship.

Competing interests:

None identified.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.